Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.63 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.63 |
| ▸ | CA1 | P00915 | 4/20 | 0.59 |
| ▸ | CA2 | P00918 | 4/20 | 0.59 |
| ▸ | ACHE | P22303 | 4/20 | 0.59 |
| ▸ | DRD2 | P14416 | 5/20 | 0.57 |
| ▸ | DRD3 | P35462 | 5/20 | 0.57 |
| ▸ | DRD4 | P21917 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | NQO2 | P16083 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8606735 | 1.00 | MTNR1A (0.63) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL8074296 | 1.00 | MTNR1A (0.63) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL8076218 | 0.94 | CA1 (0.59) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL8603697 | 0.94 | CA1 (0.59) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL8066286 | 0.94 | CA1 (0.59) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL388601 | 0.88 | MTNR1A (0.54) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL345882 | 0.87 | MTNR1A (0.60) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL8603880 | 0.87 | MTNR1A (0.60) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL345881 | 0.87 | MTNR1A (0.60) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL10197905 | 0.86 | MTNR1A (0.48) | MTNR1AMTNR1BCA1CA2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139484-A1 | DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | GOSSAMER BIO SERVICES INC (US) | 2021-05-13 | — | — | US | disclosed |
| WO-2019200120-A1 | DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | LYCERA CORPORATION (US) | 2019-10-17 | — | — | WO | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| EP-1957460-A1 | BICYCLIC COMPOUNDS WITH KINASE INHIBITORY ACTIVITY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2007067444-A1 | BICYCLIC COMPOUNDS WITH KINASE INHIBITORY ACTIVITY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| EP-0683236-B1 | Enzymatic process for the preparation of optical active tetralin-derivatives | SANOFI SYNTHELABO (FR) | 2000-08-09 | — | — | EP | disclosed |
| US-5719308-A | Enzymatic process for the preparation of optically active tetralin derivatives | SANOFI (FR) | 1998-02-17 | — | — | US | disclosed |
| US-5573949-A | Enzymatic process for the preparation of optically active Tetrahydro-2-naphthoic acids | SANOFI (FR) | 1996-11-12 | — | — | US | disclosed |
| EP-0683236-A1 | Enzymatic process for the preparation of optical active tetralin-derivatives | SANOFI (FR) | 1995-11-22 | — | — | EP | disclosed |
| EP-0678579-A1 | Enzymatic process for the preparation of optical active tetralin-derivatives | MIDY S.p.A. (IT) | 1995-10-25 | — | — | EP | disclosed |
| EP-0292977-B1 | ALKOXY-SUBSTITUTED DIHYDROBENZOPYRAN-2-CARBOXYLATE DERIVATIVES | G.D. Searle & Co. (US) | 1991-09-04 | — | — | EP | disclosed |
| US-4889871-A | ANTIINFLAMMATORY AGENTS; SELECTIVE LEUKOTRIENE ANTAGONISTS | G. D. SEARLE & CO. (US) | 1989-12-26 | — | — | US | disclosed |
| EP-0300404-A2 | Di-and tetrahydronapthyl anti-allergy agents | G.D. Searle & Co. (US) | 1989-01-25 | — | — | EP | disclosed |
| EP-0292977-A1 | Alkoxy-substituted dihydrobenzopyran-2-carboxylate derivatives | G.D. Searle & Co. (US) | 1988-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | MTNR1A 1579/4885MTNR1B 1240/4885CA1 400/4885 |
| US-20210139484-A1 | DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | ULK1, PHKG2, PHKG1 | MTNR1A 1179/4885MTNR1B 1895/4885CA1 3060/4885 |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | MTNR1A 4246/4885MTNR1B 3824/4885CA1 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.